

Autoimmunity in Chronic Obstructive Pulmonary Disease.

Gepubliceerd: 25-03-2010 Laatste bijgewerkt: 18-08-2022

Chronic Obstructive Pulmonary Disease is a disease of the lungs for which adequate treatment lacks. We hypothesize that there is a role for autoimmunity in this disease.

Ethische beoordeling	Positief advies
Status	Werving nog niet gestart
Type aandoening	-
Onderzoekstype	Observationeel onderzoek, zonder invasieve metingen

Samenvatting

ID

NL-OMON26251

Bron

NTR

Aandoening

Chronic Obstructive Pulmonary Disease, COPD, Autoimmunity, lung, smoking, cytotoxicity, antibodies

Chronische Obstructieve Bronchitis en Longemfyseem, autoimmuniteit, long, roken, cytotoxiciteit, antilichamen

Ondersteuning

Primaire sponsor: Universitair Medisch Centrum Groningen

Hanzeplein 1

Postbus 30.001

9700 RB Groningen

The Netherlands

Overige ondersteuning: Dutch Asthma Foundation

Onderzoeksproduct en/of interventie

Uitkomstmaten

Primaire uitkomstmaten

1. The degree of autoantibody-mediated cytotoxicity of sera of COPD patients when compared to non-COPD patients, expressed as a fraction of cells that have died during incubation;

2. The cell types (primary bronchial epithelial cells, primary airway smooth muscle cells, primary lung fibroblasts) and cell lines (an alveolar epithelial cell line and a lung fibroblast cell line) that are primarily affected by autoantibodies as found in serum of COPD patients and healthy controls;

3. The contribution of complement, different effector cells, and antibody-free serum to the level (as outlined in the previous paragraphs) and specificity of cytotoxicity (which cells and cell lines are affected). The impact of different effector cells and antibody-free serum.

Toelichting onderzoek

Achtergrond van het onderzoek

N/A

Doel van het onderzoek

Chronic Obstructive Pulmonary Disease is a disease of the lungs for which adequate treatment lacks. We hypothesize that there is a role for autoimmunity in this disease.

Onderzoeksopzet

N/A

Onderzoeksproduct en/of interventie

N/A

Contactpersonen

Publiek

Joost Wessels
[default]
The Netherlands
+31 (0)50 3614464

Wetenschappelijk

Joost Wessels
[default]
The Netherlands
+31 (0)50 3614464

Deelname eisen

Belangrijkste voorwaarden om deel te mogen nemen (Inclusiecriteria)

Inclusion criteria for COPD patients:

1. Clinical diagnose of COPD;
2. No allergies;
3. Post-bronchodilator FEV1 < 80% predicted, and postbronchodilator FEV1/FVC < 70% (in accordance with the GOLD stages mentioned above);
4. Age > 40;
5. Current or ex-smokers > 10 pack years;
6. Ex-smokers have to have quitted smoking for at least one year;
7. No other major current health problems;
8. Written informed consent.

Healthy controls:

1. No signs of pulmonary disease;

2. No allergies;
3. No other major current health problems;
4. FEV1 > 90 % predicted and FEV1/FVC > 70%;
5. Age > 40;
6. Never smokers, i.e. no cigarettes last year, and < 5 pack years, or current smokers > 10 pack years; or ex- smokers for > 1 year and > 10 pack years;
7. Written informed consent.

Belangrijkste redenen om niet deel te kunnen nemen (Exclusiecriteria)

1. Addiction to alcohol or drugs;
2. COPD exacerbation in the 6 weeks preceding the study;
3. Immunosuppressive therapy.

Onderzoeksopzet

Opzet

Type:	Observationeel onderzoek, zonder invasieve metingen
Onderzoeksmodel:	Parallel
Toewijzing:	Niet-gerandomiseerd
Controle:	N.v.t. / onbekend

Deelname

Nederland	
Status:	Werving nog niet gestart
(Verwachte) startdatum:	01-04-2010
Aantal proefpersonen:	120
Type:	Verwachte startdatum

Ethische beoordeling

Positief advies

Datum: 25-03-2010

Soort: Eerste indiening

Registraties

Opgevolgd door onderstaande (mogelijk meer actuele) registratie

Geen registraties gevonden.

Andere (mogelijk minder actuele) registraties in dit register

Geen registraties gevonden.

In overige registers

Register	ID
NTR-new	NL2135
NTR-old	NTR2259
Ander register	Dutch Asthma Foundation : 3.2.08.021
ISRCTN	ISRCTN wordt niet meer aangevraagd.

Resultaten

Samenvatting resultaten

N/A